# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**
**March 1, 2021**

# MATEON THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)**

| **Delaware** | **000-21990** | **13-3679168** |
|---|---|---|
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

**29397 Agoura Road Suite 107**
**Agoura Hills, CA 91301**
**(Address of principal executive offices and Zip Code)**

**Registrant's telephone number, including area code**
**(650) 635-7000**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of class | Trading Symbols | Name of each exchange on which registered |
|---|---|---|
| N/A | | |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

**Item 8.01 Other Events**

On March 1, 2021 Mateon Therapeutics, Inc. issued press release announcing:

We have shown that the active component of PulmoHeal™ is active against influenza virus consistent with the broad-spectrum activity for PulmoHealTM which is confirmed by its reported activity against variants, B1.1.7 and B1.351 of SARS-CoV-2. These escape variants have been reported to be more contagious and potentially resistant to vaccines.

Additionally, Mateon has further its relationship with IBM by signing a joint development agreement with IBM Watson Health Research division to collectively work on AI models for respiratory assessments.

The press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit No. | Description | Incorporation by reference |
|---|---|---|
| 99.1 | Publications of PulmoHeal | Filed herewith. |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Mateon Therapeutics, Inc.

Date: March 2, 2021

*/s/ Vuong Trieu*

By: Vuong Trieu
Chief Executive Officer

**Exhibit 99.1**

**MATEON THERAPEUTICS AND WINDLAS BIOTECH PUBLISH PULMOHEAL™ CLINICAL DATA AGAINST COVID-19 IN PEER-REVIEWED JOURNALS**

**AGOURA HILLS, California, March 1, 2021 (GLOBE NEWSWIRE) —** Mateon Therapeutics, Inc. (OTCQB:MATN) ("Mateon"), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, and Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract drug development and manufacturing organization, announced today the publication of ARTI-19 in peer-reviewed journals. ARTI-19 is "A Prospective, Randomized, Multi-center, Open-label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19".

"More patients recovered faster when PulmoHeal™ was used as adjunct therapy alongside standard of care (SOC). This was observed across all sites, including Remdesivir-based SOC at site 201, Dexamethasone/Heparin-based SOC at site 202, and Ivermectin-based SOC at site 203." said Dr. Vuong Trieu, CEO and Chairman of Mateon.

"More importantly, we have shown that the active component of PulmoHeal™ is active against influenza virus consistent with the broad-spectrum activity for PulmoHeal™ which is confirmed by its reported activity against multiple variants of SARS-CoV2: WT (USA/WA12020) SARS-CoV-2 and variants, B1.1.7 and B1.351." said Saran Saund, CBO and GM of AI Division, Mateon.

The publications are as follow:

**1)** Vuong Trieu, Saran Saund, Prashant V. Rahate, Viljay B. Barge, K. Sunil Nalk, Hitesh Windlass, Fatih M. Uckun. "Targeting TGF-b pathway with COVID-19 Drug Candidate PulmoHeal/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19". 2021. The Journal of Clinical Investigation (London) (2021) 11(1), 10-18. https://www.openaccessjournals.com/articles/targeting-tgf-pathway-with-covid19-drug-candidate-artivedapulmoheal-accelerates-recovery-from-mildmoderate-covid19.pdf

2) Fatih M. M. Uckun, M.D., Ph.D* , Saran Saund, Hitesh Windlass and Vuong Trieu. "Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug. Mini Review", Frontiers of Pharmacololgy Journal. Experimental Pharmacology and Drug Discovery. 2021. https://www.frontiersin.org/articles/10.3389/fphar.2021.649532/abstract

3) Naira, M.S., Huang, Y., Fidock, D.A.,Polyak, S.J., Wagonerd, J.,Towlere, M.J., Weatherse, P.J. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants. bioRxiv preprint doi: https://doi.org/10.1101/2021.01.08.425825.

"We are excited with the developing data around PulmoHeal™ especially the data on the escape variants which are more contagious and potentially resistant to vaccines. We will be having an expert panel discussion on PulmoHeal™ on March 5th, 2021. Additional information will be provided at www.pulmoheal.com." said Mr Hitesh Windlass, MD, Windlas Biotech.

**About PulmoHeal™:** PulmoHeal™ consists of three components:

- A mobile app called ArtiHealth™ powered by Mateon's AI platform that allows patients to submit a questionnaire and a daily cough recording to receive real-time information on their respiratory function and progress over time. Mateon has signed a joint development agreement with IBM Watson Health Research division to collectively work on AI models for respiratory assessments from Mateon's data collection initiatives.
- A post-marketing survey (PMS) platform to crowd-source user experience for new indications.
- The drug PulmoHeal™, a broad-spectrum, lung therapy food supplement that is supported by a multi-center rigorous clinical study that has demonstrated efficacy against the viral respiratory infection- COVID-19;
- Additional information at www.pulmoheal.com

**About Mateon Therapeutics**: Mateon was created by the 2019 merger with Oncotelic, which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare paediatric cancers. Mateon has rare paediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.mateon.com.

**About Windlas Biotech Pvt. Ltd, India:** Windlas is a 20-year-old company with a strong track record of research, development, manufacturing, and distribution of pharmaceutical products in India, USA and several other emerging markets. It has four large scale manufacturing facilities employing more than 1500 employees and is the 5th largest Contract Development and Manufacturing Organization (CDMO) serving top innovator as well as generic pharma companies across the world. It has developed more than 500 different formulations (> 2Billion doses annually) of anti-viral, cardiovascular, anti-diabetic, anti-infective, CNS and dermatology products. For more information, please visit https://windlas.com/

**About AI Telemedicine platform:** Mateon's AI telemedicine platform combines a mobile app called ArtiHealth™ for consumers to self-monitor their respiratory health using AI-driven logic. It also enables a post-marketing survey to allow crowd sourcing of data from patients to provide large scale real world clinical data necessary for a evaluation of PulmoHeal™ in respiratory diseases such as COPD and asthma. A QR code on the product package allows consumers to download the app on their mobile device. For additional information, please visit: www.pulmoheal.com.

**Mateon's Cautionary Note on Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company's annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com

******